MedTrace Logo

De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

NCT03822897 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2026-02-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.

Conditions

  • Oropharyngeal Cancer

Interventions

RADIATION

Radiation

35 fractions, 5/wk, 7 wks 70Gy/56Gy, or 35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or 35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy

DRUG

Cisplatin

100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Scott Bratman · Princess Margaret Cancer Centre, Toronto, ON

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-28
Primary Completion
2024-06-25
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822897 on ClinicalTrials.gov